Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort
Abstract Introduction Vaccination plays a fundamental role in mastering the COVID‐19 pandemic and protecting vulnerable groups. Persons with autoimmune inflammatory rheumatic diseases (AIIRD) requiring immunosuppressive therapies are prioritized for vaccination. However, data concerning immunogenici...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.858 |
| _version_ | 1797816622608547840 |
|---|---|
| author | Batool Zamani Amin Moradi Hasan‐Abad Ahmad Piroozmand Mahsa Dehghani Maryam Arfaatabar Hossein Motedayyen |
| author_facet | Batool Zamani Amin Moradi Hasan‐Abad Ahmad Piroozmand Mahsa Dehghani Maryam Arfaatabar Hossein Motedayyen |
| author_sort | Batool Zamani |
| collection | DOAJ |
| description | Abstract Introduction Vaccination plays a fundamental role in mastering the COVID‐19 pandemic and protecting vulnerable groups. Persons with autoimmune inflammatory rheumatic diseases (AIIRD) requiring immunosuppressive therapies are prioritized for vaccination. However, data concerning immunogenicity and safety of the BBIBP‐CorV vaccine in immunosuppressed patients are not found. This study presents data on the efficacy and safety of the BBIBP‐CorV vaccine in immunosuppressed patients compared to healthy controls. Methods Study population consisted of 100 healthy controls and 100 patients with AIIRD. Vaccination was performed according to national guidelines with the BBIBP‐CorV vaccine. SARS‐CoV‐2 neutralizing antibody titers were quantified by enzyme‐linked immunosorbent assay before initial vaccination and 1–3 months after secondary vaccination. Adverse events were assessed before study initiation and 7 days after the second dose. Disease activity was studied before entering the study and 3–8 weeks after the second dose. Results Vaccination‐induced positive immunogenic response rates and SARS‐CoV‐2 neutralizing antibody titers were significantly lower in the AIIRD patients than healthy subjects (p < .05). There are significant differences in neutralizing antibody titers among patients suffering from rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis, and ankylosing spondylitis (p < .01–.05). The rates of seropositive vaccine responses were similarly distributed across all diseases. Healthy and AIIRD individuals had a similar profile in adverse events. No significant difference was observed in SARS‐CoV‐2 antibody titers between subjects suffering from side effects and those who did not have. SARS‐CoV‐2 neutralizing antibody levels were significantly higher in subjects with a history of COVID‐19 infection than seronegative individuals (p < .01–0.05). Seropositive subjects had a significant increase in the percentage of vaccine‐related adverse events compared to seronegative persons (p < .05). Despite a minor change in the disease activity of patients with RA and SLE, disease activity indices were overall stable in the AIIRD patients. Conclusion These findings revealed that the BBIBP‐CorV vaccine is effective in the development of neutralizing antibodies in immunosuppressed patients without considerable reactogenicity or induction of disease flares. |
| first_indexed | 2024-03-13T08:40:22Z |
| format | Article |
| id | doaj.art-b968e546511648288eb6e48ea8fa6277 |
| institution | Directory Open Access Journal |
| issn | 2050-4527 |
| language | English |
| last_indexed | 2024-03-13T08:40:22Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj.art-b968e546511648288eb6e48ea8fa62772023-05-30T12:34:31ZengWileyImmunity, Inflammation and Disease2050-45272023-05-01115n/an/a10.1002/iid3.858Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohortBatool Zamani0Amin Moradi Hasan‐Abad1Ahmad Piroozmand2Mahsa Dehghani3Maryam Arfaatabar4Hossein Motedayyen5Autoimmune Diseases Research Center Kashan University of Medical Sciences Kashan IranAutoimmune Diseases Research Center Kashan University of Medical Sciences Kashan IranAutoimmune Diseases Research Center Kashan University of Medical Sciences Kashan IranAutoimmune Diseases Research Center Kashan University of Medical Sciences Kashan IranDepartment of Medical Laboratory Sciences, Kashan Branch Islamic Azad University Kashan IranAutoimmune Diseases Research Center Kashan University of Medical Sciences Kashan IranAbstract Introduction Vaccination plays a fundamental role in mastering the COVID‐19 pandemic and protecting vulnerable groups. Persons with autoimmune inflammatory rheumatic diseases (AIIRD) requiring immunosuppressive therapies are prioritized for vaccination. However, data concerning immunogenicity and safety of the BBIBP‐CorV vaccine in immunosuppressed patients are not found. This study presents data on the efficacy and safety of the BBIBP‐CorV vaccine in immunosuppressed patients compared to healthy controls. Methods Study population consisted of 100 healthy controls and 100 patients with AIIRD. Vaccination was performed according to national guidelines with the BBIBP‐CorV vaccine. SARS‐CoV‐2 neutralizing antibody titers were quantified by enzyme‐linked immunosorbent assay before initial vaccination and 1–3 months after secondary vaccination. Adverse events were assessed before study initiation and 7 days after the second dose. Disease activity was studied before entering the study and 3–8 weeks after the second dose. Results Vaccination‐induced positive immunogenic response rates and SARS‐CoV‐2 neutralizing antibody titers were significantly lower in the AIIRD patients than healthy subjects (p < .05). There are significant differences in neutralizing antibody titers among patients suffering from rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis, and ankylosing spondylitis (p < .01–.05). The rates of seropositive vaccine responses were similarly distributed across all diseases. Healthy and AIIRD individuals had a similar profile in adverse events. No significant difference was observed in SARS‐CoV‐2 antibody titers between subjects suffering from side effects and those who did not have. SARS‐CoV‐2 neutralizing antibody levels were significantly higher in subjects with a history of COVID‐19 infection than seronegative individuals (p < .01–0.05). Seropositive subjects had a significant increase in the percentage of vaccine‐related adverse events compared to seronegative persons (p < .05). Despite a minor change in the disease activity of patients with RA and SLE, disease activity indices were overall stable in the AIIRD patients. Conclusion These findings revealed that the BBIBP‐CorV vaccine is effective in the development of neutralizing antibodies in immunosuppressed patients without considerable reactogenicity or induction of disease flares.https://doi.org/10.1002/iid3.858adverse eventsBBIBP‐CorV vaccinedisease activityimmunogenicitypatients with AIIRD |
| spellingShingle | Batool Zamani Amin Moradi Hasan‐Abad Ahmad Piroozmand Mahsa Dehghani Maryam Arfaatabar Hossein Motedayyen Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort Immunity, Inflammation and Disease adverse events BBIBP‐CorV vaccine disease activity immunogenicity patients with AIIRD |
| title | Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort |
| title_full | Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort |
| title_fullStr | Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort |
| title_full_unstemmed | Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort |
| title_short | Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort |
| title_sort | immunogenicity and safety of the bbibp corv vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort |
| topic | adverse events BBIBP‐CorV vaccine disease activity immunogenicity patients with AIIRD |
| url | https://doi.org/10.1002/iid3.858 |
| work_keys_str_mv | AT batoolzamani immunogenicityandsafetyofthebbibpcorvvaccineinpatientswithautoimmuneinflammatoryrheumaticdiseasesundergoingimmunosuppressivetherapyinamonocentriccohort AT aminmoradihasanabad immunogenicityandsafetyofthebbibpcorvvaccineinpatientswithautoimmuneinflammatoryrheumaticdiseasesundergoingimmunosuppressivetherapyinamonocentriccohort AT ahmadpiroozmand immunogenicityandsafetyofthebbibpcorvvaccineinpatientswithautoimmuneinflammatoryrheumaticdiseasesundergoingimmunosuppressivetherapyinamonocentriccohort AT mahsadehghani immunogenicityandsafetyofthebbibpcorvvaccineinpatientswithautoimmuneinflammatoryrheumaticdiseasesundergoingimmunosuppressivetherapyinamonocentriccohort AT maryamarfaatabar immunogenicityandsafetyofthebbibpcorvvaccineinpatientswithautoimmuneinflammatoryrheumaticdiseasesundergoingimmunosuppressivetherapyinamonocentriccohort AT hosseinmotedayyen immunogenicityandsafetyofthebbibpcorvvaccineinpatientswithautoimmuneinflammatoryrheumaticdiseasesundergoingimmunosuppressivetherapyinamonocentriccohort |